# A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Solid Tumors

> **NCT05039931** · PHASE1 · WITHDRAWN · sponsor: **Sichuan Baili Pharmaceutical Co., Ltd.**

## Conditions studied

- Breast Cancer
- Solid Tumor

## Interventions

- **DRUG:** GNC-035

## Key facts

- **NCT ID:** NCT05039931
- **Lead sponsor:** Sichuan Baili Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-09-15
- **Primary completion:** 2023-06
- **Final completion:** 2023-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** leading entity of the clinical trial was replaced, and no patients were enrolled.
- **Last updated:** 2024-07-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05039931

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05039931, "A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05039931. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*